(0)サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1605923

転移性肺腺がん治療市場、規模、シェア、動向、産業分析レポート：治療別、エンドユーザー別、地域別 - 市場予測 2025年～2034年

Metastatic Lung Adenocarcinoma Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment, End User, and Region - Market Forecast, 2025-2034

出版日
ページ情報
英文 119 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.87円
転移性肺腺がん治療市場、規模、シェア、動向、産業分析レポート：治療別、エンドユーザー別、地域別 - 市場予測 2025年～2034年
出版日: 2024年11月01日
発行: Polaris Market Research
ページ情報: 英文 119 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界の転移性肺腺がん治療市場規模は2034年までに141億7,000万米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

転移性肺腺がん治療市場の成長は、患者の転帰を大幅に改善する標的治療や免疫療法の進歩、肺がんの有病率の増加、個別化医療に対する需要の高まりに起因しています。

特にEGFRやALKのような特定の遺伝子変異を標的とした新規治療法の開拓は、今後数年間、市場にチャンスをもたらすと思われます。動向は、治療効果を高めるための併用療法やバイオマーカー主導型アプローチへの注目が高まっていることを示しています。全体として、製薬企業がこの患者集団の新興国市場のニーズの高まりに対応するために研究開発に多額の投資を行うことで、市場は拡大すると予想されます。

転移性肺腺がん治療市場レポート・ハイライト

治療別では、免疫療法が持続的な奏効と生存率の改善により市場を独占しています。標的治療分野も、特にEGFRのような遺伝子変異が確認された患者において大きな伸びを示しています。

エンドユーザー別では、病院セグメントが転移性肺腺がん治療市場の最大株主であり続けているが、これは高度な治療オプションと包括的なケア施設が利用可能であることが背景にあります。専門クリニック分野は、集中的かつ個別化されたがん治療に対する需要の高まりに対応し、急速に成長しています。

北米は世界の転移性肺腺がん治療市場を独占しているが、これは大手製薬会社の存在と高度なヘルスケアインフラに起因しています。アジア太平洋は、がん罹患率の上昇とヘルスケア投資の増加に後押しされ、最も急成長している市場です。

AstraZeneca, Roche, Merck & Co., Bristol-Myers Squibb, Pfizer, Novartis, Eli Lilly and Company, Amgen, Sanofi, Boehringer Ingelheim, Takeda Pharmaceutical Company, Johnson & Johnson, AbbVie, Bayer, and GlaxoSmithKlineが転移性肺腺がん治療市場の主要企業です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 転移性肺腺がん治療の世界市場の洞察

  • 市場スナップショット
  • 転移性肺腺がん治療市場力学
    • 促進要因と機会
      • 標的療法への注目の高まり
      • 免疫療法の進歩
    • 抑制要因と課題
      • 生存率が低い
  • PESTEL分析
  • 転移性肺腺がん治療市場の動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 転移性肺腺がん治療の世界市場：治療別

  • 主な調査結果
  • イントロダクション
  • 化学療法
  • 標的療法
  • 免疫療法
  • 治療
  • その他

第6章 世界の転移性肺腺がん治療市場：エンドユーザー別

  • 主な調査結果
  • イントロダクション
  • 病院
  • 専門クリニック
  • その他

第7章 世界の転移性肺腺がん治療市場：地域別

  • 主な調査結果
  • イントロダクション
    • 転移性肺腺がん治療市場評価：地域、2020～2034年
  • 北米
    • 北米：治療別、2020～2034年
    • 北米：エンドユーザー別、2020～2034年
    • 米国
    • カナダ
  • 欧州
    • 欧州：治療別、2020～2034年
    • 欧州：エンドユーザー別、2020～2034年
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • オランダ
    • ロシア
    • その他欧州
  • アジア太平洋
    • アジア太平洋地域：治療別、2020～2034年
    • アジア太平洋地域：エンドユーザー別、2020～2034年
    • 中国
    • インド
    • マレーシア
    • 日本
    • インドネシア
    • 韓国
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ
    • 中東・アフリカ：治療別、2020～2034年
    • 中東・アフリカ：エンドユーザー別、2020～2034年
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ
  • ラテンアメリカ
    • ラテンアメリカ：治療別、2020～2034年
    • ラテンアメリカ：エンドユーザー別、2020～2034年
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他ラテンアメリカ

第8章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第9章 企業プロファイル

  • AstraZeneca
  • Roche
  • Merck & Co
  • Bristol-Myers Squibb
  • Pfizer
  • Novartis
  • Eli Lilly and Company
  • Amgen
  • Sanofi
  • Boehringer Ingelheim
  • Takeda Pharmaceutical Company
図表

List of Tables:

  • Table 1 Global Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 2 Global Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 3 North America: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 4 North America: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 5 U.S.: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 6 U.S.: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 7 Canada: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 8 Canada: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 9 Europe: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 10 Europe: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 11 UK: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 12 UK: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 13 France: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 14 France: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 15 Germany: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 16 Germany: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 17 Italy: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 18 Italy: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 19 Spain: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 20 Spain: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 21 Netherlands: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 22 Netherlands: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 23 Russia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 24 Russia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 25 Rest of Europe: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 26 Rest of Europe: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 27 Asia Pacific: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 28 Asia Pacific: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 29 China: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 30 China: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 31 India: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 32 India: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 33 Malaysia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 34 Malaysia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 35 Japan: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 36 Japan: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 37 Indonesia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 38 Indonesia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 39 South Korea: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 40 South Korea: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 41 Australia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 42 Australia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 43 Rest of Asia Pacific: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 44 Rest of Asia Pacific: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 45 Middle East & Africa: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 46 Middle East & Africa: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 47 Saudi Arabia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 48 Saudi Arabia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 49 UAE: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 50 UAE: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 51 Israel: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 52 Israel: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 53 South Africa: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 54 South Africa: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 55 Rest of Middle East & Africa: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 56 Rest of Middle East & Africa: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 57 Latin America: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 58 Latin America: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 59 Mexico: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 60 Mexico: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 61 Brazil: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 62 Brazil: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 63 Argentina: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 64 Argentina: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 65 Rest of Latin America: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 66 Rest of Latin America: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • List of Figures:
  • Figure 1. Global Metastatic Lung Adenocarcinoma Treatment Market, 2020-2034 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Treatment
  • Figure 7. Global Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2024 & 2034 (USD Billion)
  • Figure 8. Market by End User
  • Figure 9. Global Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2024 & 2034 (USD Billion)
目次
Product Code: PM5255

The global metastatic lung adenocarcinoma treatment market size is expected to reach USD 14.17 billion by 2034, according to a new study by Polaris Market Research. The report "Metastatic Lung Adenocarcinoma Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, and Others), End User (Hospitals, Specialty Clinics, and Others), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The metastatic lung adenocarcinoma treatment market growth can be attributed to advancements in targeted therapies and immunotherapies that are significantly improving patient outcomes, increasing prevalence of lung cancer, and the rising demand for personalized medicine.

The development of novel treatment options, particularly those targeting specific genetic mutations such as EGFR and ALK, would offer opportunities for the market in the coming years. Trends indicate a growing focus on combination therapies and biomarker-driven approaches to enhance treatment efficacy. Overall, the market is expected to expand as pharmaceutical companies invest heavily in research and development to meet the evolving needs of this patient population.

Metastatic Lung Adenocarcinoma Treatment Market Report Highlights:

Based on treatment, the immunotherapy segment dominates the market due to its ability to provide durable responses and improved survival rates. The targeted therapy segment is also seeing significant growth, particularly in patients with identifiable genetic mutations such as EGFR.

In terms of end users, the hospital segment remains the largest shareholder in the metastatic lung adenocarcinoma treatment market, driven by the availability of advanced treatment options and comprehensive care facilities. The specialty clinics segment is growing rapidly, catering to the increasing demand for focused and personalized cancer treatment.

North America dominates the global metastatic lung adenocarcinoma treatment market, attributed to the presence of major pharmaceutical companies and advanced healthcare infrastructure. Asia Pacific is the fastest-growing market, propelled by rising cancer incidence rates and increasing healthcare investments.

AstraZeneca, Roche, Merck & Co., Bristol-Myers Squibb, Pfizer, Novartis, Eli Lilly and Company, Amgen, Sanofi, Boehringer Ingelheim, Takeda Pharmaceutical Company, Johnson & Johnson, AbbVie, Bayer, and GlaxoSmithKline are among the key players in the metastatic lung adenocarcinoma treatment market.

Polaris Market Research has segmented the metastatic lung adenocarcinoma treatment market report on the basis of treatment, end user, and region:

By Treatment Outlook (Revenue - USD Billion, 2020-2034)

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Radiation Therapy
  • Others

By End User Outlook (Revenue - USD Billion, 2020-2034)

  • Hospitals
  • Specialty Clinics
  • Others

By Regional Outlook (Revenue - USD Billion, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Metastatic Lung Adenocarcinoma Treatment Market Insights

  • 4.1. Metastatic Lung Adenocarcinoma Treatment Market - Market Snapshot
  • 4.2. Metastatic Lung Adenocarcinoma Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increased Focus on Targeted Therapies
      • 4.2.1.2. Advancements in Immunotherapy
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Low Survival Rates
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Metastatic Lung Adenocarcinoma Treatment Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Metastatic Lung Adenocarcinoma Treatment Market, by Treatment

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • 5.3. Chemotherapy
    • 5.3.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Chemotherapy, by Region, 2020-2034 (USD Billion)
  • 5.4. Targeted Therapy
    • 5.4.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Targeted Therapy, by Region, 2020-2034 (USD Billion)
  • 5.5. Immunotherapy
    • 5.5.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Immunotherapy, by Region, 2020-2034 (USD Billion)
  • 5.6. Therapy
    • 5.6.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Radiation Therapy, by Region, 2020-2034 (USD Billion)
  • 5.7. Others
    • 5.7.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Others, by Region, 2020-2034 (USD Billion)

6. Global Metastatic Lung Adenocarcinoma Treatment Market, by End User

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 6.3. Hospitals
    • 6.3.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Hospitals, by Region, 2020-2034 (USD Billion)
  • 6.4. Specialty Clinics
    • 6.4.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Specialty Clinics, by Region, 2020-2034 (USD Billion)
  • 6.5. Others
    • 6.5.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Metastatic Lung Adenocarcinoma Treatment Market, by Geography

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Metastatic Lung Adenocarcinoma Treatment Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 7.3. Metastatic Lung Adenocarcinoma Treatment Market - North America
    • 7.3.1. North America: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.3.2. North America: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.3.3. Metastatic Lung Adenocarcinoma Treatment Market - U.S.
      • 7.3.3.1. U.S.: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.3.3.2. U.S.: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.3.4. Metastatic Lung Adenocarcinoma Treatment Market - Canada
      • 7.3.4.1. Canada: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.3.4.2. Canada: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.4. Metastatic Lung Adenocarcinoma Treatment Market - Europe
    • 7.4.1. Europe: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.4.2. Europe: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.4.3. Metastatic Lung Adenocarcinoma Treatment Market - UK
      • 7.4.3.1. UK: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.4.3.2. UK: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.4.4. Metastatic Lung Adenocarcinoma Treatment Market - France
      • 7.4.4.1. France: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.4.4.2. France: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.4.5. Metastatic Lung Adenocarcinoma Treatment Market - Germany
      • 7.4.5.1. Germany: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.4.5.2. Germany: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.4.6. Metastatic Lung Adenocarcinoma Treatment Market - Italy
      • 7.4.6.1. Italy: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.4.6.2. Italy: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.4.7. Metastatic Lung Adenocarcinoma Treatment Market - Spain
      • 7.4.7.1. Spain: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.4.7.2. Spain: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.4.8. Metastatic Lung Adenocarcinoma Treatment Market - Netherlands
      • 7.4.8.1. Netherlands: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.4.8.2. Netherlands: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.4.9. Metastatic Lung Adenocarcinoma Treatment Market - Russia
      • 7.4.9.1. Russia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.4.9.2. Russia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.4.10. Metastatic Lung Adenocarcinoma Treatment Market - Rest of Europe
      • 7.4.10.1. Rest of Europe: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.4.10.2. Rest of Europe: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.5. Metastatic Lung Adenocarcinoma Treatment Market - Asia Pacific
    • 7.5.1. Asia Pacific: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.5.2. Asia Pacific: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.5.3. Metastatic Lung Adenocarcinoma Treatment Market - China
      • 7.5.3.1. China: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.5.3.2. China: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.5.4. Metastatic Lung Adenocarcinoma Treatment Market - India
      • 7.5.4.1. India: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.5.4.2. India: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.5.5. Metastatic Lung Adenocarcinoma Treatment Market - Malaysia
      • 7.5.5.1. Malaysia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.5.5.2. Malaysia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.5.6. Metastatic Lung Adenocarcinoma Treatment Market - Japan
      • 7.5.6.1. Japan: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.5.6.2. Japan: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.5.7. Metastatic Lung Adenocarcinoma Treatment Market - Indonesia
      • 7.5.7.1. Indonesia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.5.7.2. Indonesia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.5.8. Metastatic Lung Adenocarcinoma Treatment Market - South Korea
      • 7.5.8.1. South Korea: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.5.8.2. South Korea: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.5.9. Metastatic Lung Adenocarcinoma Treatment Market - Australia
      • 7.5.9.1. Australia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.5.9.2. Australia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.5.10. Metastatic Lung Adenocarcinoma Treatment Market - Rest of Asia Pacific
      • 7.5.10.1. Rest of Asia Pacific: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.5.10.2. Rest of Asia Pacific: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.6. Metastatic Lung Adenocarcinoma Treatment Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.6.2. Middle East & Africa: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.6.3. Metastatic Lung Adenocarcinoma Treatment Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.6.4. Metastatic Lung Adenocarcinoma Treatment Market - UAE
      • 7.6.4.1. UAE: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.6.4.2. UAE: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.6.5. Metastatic Lung Adenocarcinoma Treatment Market - Israel
      • 7.6.5.1. Israel: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.6.5.2. Israel: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.6.6. Metastatic Lung Adenocarcinoma Treatment Market - South Africa
      • 7.6.6.1. South Africa: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.6.6.2. South Africa: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.6.7. Metastatic Lung Adenocarcinoma Treatment Market - Rest of Middle East & Africa
      • 7.6.7.1. Rest of Middle East & Africa: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.6.7.2. Rest of Middle East & Africa: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.7. Metastatic Lung Adenocarcinoma Treatment Market - Latin America
    • 7.7.1. Latin America: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.7.2. Latin America: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.7.3. Metastatic Lung Adenocarcinoma Treatment Market - Mexico
      • 7.7.3.1. Mexico: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.7.3.2. Mexico: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.7.4. Metastatic Lung Adenocarcinoma Treatment Market - Brazil
      • 7.7.4.1. Brazil: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.7.4.2. Brazil: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.7.5. Metastatic Lung Adenocarcinoma Treatment Market - Argentina
      • 7.7.5.1. Argentina: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.7.5.2. Argentina: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.7.6. Metastatic Lung Adenocarcinoma Treatment Market - Rest of Latin America
      • 7.7.6.1. Rest of Latin America: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.7.6.2. Rest of Latin America: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. AstraZeneca
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Roche
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Merck & Co
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Bristol-Myers Squibb
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Pfizer
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Novartis
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Eli Lilly and Company
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Amgen
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Sanofi
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Boehringer Ingelheim
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Takeda Pharmaceutical Company
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development